Hagop Kantarjian, MD, on Blinatumomab in Precursor B-Cell ALL

2014 ASH Annual Meeting

Hagop Kantarjian, MD, of The University of Texas MD Anderson Cancer Center, offers his thoughts on abstract 379, “BLAST: A Confirmatory, Single-Arm, Phase II Study of Blinatumomab, a Bispecific T-Cell Engager (BiTE) Antibody Construct, in Patients With Minimal Residual Disease B-Precursor Acute Lymphoblastic Leukemia,” and abstract 3704, “An Evaluation of Molecular Response in a Phase II Open-Label, Multicenter Confirmatory Study in Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia Receiving Treatment With the BiTE Antibody Construct Blinatumomab,” presented by Nicola Gökbuget, MD.

Alan F. List, MD, and James O. Armitage, MD, FACP, FRCP, on Advances in Myelodysplastic Syndrome

Alan F. List, MD, of Moffitt Cancer Center and the University of South Florida, and James O. Armitage, MD, FACP, FRCP, of the University of Nebraska Medical Center, discuss the biology and diagnostic criteria for myelodysplastic syndrome, as well as advances in the disease presented at the 56th ASH Annual Meeting.

Myelodysplastic Syndromes

Leukemia

Alan F. List, MD

Time: 1:11

Hematologic Malignancies

Ayalew Tefferi, MD

Ayalew Tefferi, MD, on Imetelstat as Therapy for Myelofibrosis

Ayalew Tefferi, MD, of the Mayo Clinic, on abstract 634, “Imetelstat, a Telomerase Inhibitor, Therapy for Myelofibrosis: A Pilot Study.”

Jan

Today In Oncology

Hagop Kantarjian, MD, on Blinatumomab in Precursor B-Cell ALL

Related Videos

Alan F. List, MD, and James O. Armitage, MD, FACP, FRCP, on Advances in Myelodysplastic Syndrome

Alan F. List, MD, on Sotatercept in Lower-Risk Myelodysplastic Syndromes

Ayalew Tefferi, MD, on New Models of Prognostication for Myelofibrosis

Linda J. Burns, MD, on the BLAST Study

Ayalew Tefferi, MD, on Imetelstat as Therapy for Myelofibrosis

Leader in Global Cancer Care, Paul E. Goss, MD, PhD, Dies at 70

New Report Shows Colorectal Cancer is Now Leading Cancer Death Among Those Under 50

Pembrolizumab Plus Lenvatinib in Recurrent Gynecologic Clear Cell Carcinoma

Cabozantinib and Temozolomide in Unresectable or Metastatic Leiomyosarcoma

Nutrition Muscle Loss Compromises Survival in Patients With Cervical Cancer Undergoing Chemoradiotherapy